Comparison of metformin plus modified release gliciazide with metformin plus sitagliptin for treatment of diabetes mellitus.

Abstract

Objective: To compare the efficacy of metformin plus modified-release gliclazide versus metformin plus sitagliptin in reducing HbA1c levels in patients with type II diabetes mellitus. Study Design: Randomized Controlled Trial. Period: August’2021 to January’2022. Setting: Medical Outdoor, Allied Hospital Faisalabad. Methods: Total 200 patients with type II diabetes mellitus of either gender of age 30-60 years were selected. Group A patients took combination of metformin (1000 mg/day) and modified release gliclazide (60 mg/day) for 12 weeks. Group B patients took combination of metformin (1000 mg/day) and sitagliption (100 mg/day) for 12 weeks. Results: The mean age of patients in group A was 43.43 ± 9.76 years and in group B was 45.83 ± 7.86 years. Out of 200 patients, 86 (43.0%) were males and 114 (57.0%) were females with male to female ratio of 1:1.3. In my study, mean HbA1c after 12 weeks of treatment with combination of metformin and Gliclazide was 6.53% ± 0.18 and with combination of metformin and sitagliptin it was 6.40% ± 0.10 (p-value = 0.0001). Conclusion: This study concluded that thecombination of Metformin and Sitagliptan is better than combination of Metformin and for modified release Gliclazid treatment of type II diabetes mellitus in terms of mean HbA1c.